30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
This week, the National Labor Relations Board (the Board) made it easier for employers to change the...
Read More >
The Mississippi Commission on Environmental Quality (“MCEQ”) and Little Bluff, LLC, (“Little Bluf...
Read More >
Agreement Resolves Claims of Sexual Harassment and Retaliation - LOS ANGELES - Sierra Creative Sys...
Read More >
CEP Magazine (November 2019) - A statute on the books in Kentucky requires companies to post a bond...
Read More >
In our previous alert, we described the sustainability reporting ecosystem shaping the disclosure pa...
Read More >
Have you ever heard of Miquela Sousa, Sophia the Robot or Shuda? These names refer to a new category...
Read More >